ChiCTR2600120684 Magnesium Sulfate Acute Lung Injury Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines ChiCTR2600120684 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 27 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why ChiCTR2600120684 is a hot trial to watch
Acute Lung Injury is being segmented by mechanism, treatment setting, geography and endpoint architecture. ChiCTR2600120684 is notable because it evaluates Magnesium Sulfate in a Phase 2 design sponsored by Shanxi Bethune Hospital. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | ChiCTR2600120684 |
| Official title | Effect of Early Intravenous Magnesium Sulfate on Clinical Outcomes in Patients with Moderate to Severe Traumatic Brain Injury |
| Phase / status | Phase 2 / Pending |
| Intervention | Magnesium Sulfate |
| Sponsor | Shanxi Bethune Hospital |
| Geography | China |
| Enrollment | 41 |
| Primary endpoint | The incidence rate of the 28-day hierarchical composite endpoint event |
| Endpoint time frame | OI was assessed during D0-D5; ARDS was assessed during D1-D7; The death monitoring during D0-D28. |
| Primary completion / readout proxy | 2027-10-31 |
Protocol design and endpoint interpretation
The indexed record describes a Phase 2 study of Magnesium Sulfate in Acute Lung Injury.
Allocation is not reported, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of 41 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- The incidence rate of the 28-day hierarchical composite endpoint event (OI was assessed during D0-D5; ARDS was assessed during D1-D7; The death monitoring during D0-D28.) — The composite endpoint analyzed using the Win Ratio (winning rate ratio) method is defined according to the following clinical priority order: 1) Death caused by any reason; 2) New-onset acute respiratory distress syndrome: in accordance with the 2023 Delphi global consensus standards; 3) No improvement in oxygenation function: the area under the curve (AUC) of the oxygenation index (PaO?/FiO?) from baseline (D0) to
Readout outlook and evidence gap
The current protocol points to 2027-10-31 as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Magnesium Sulfate is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Shanxi Bethune Hospital is resolved to a normalized organization record in No normalized location returned. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
ChiCTR2600120684 provides a focused lens on Acute Lung Injury development. Its value will be determined by whether Magnesium Sulfate can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
